COMP <GO>
MGRX vs JNJ // PIOTROSKI F-SCORE QUALITY
Mangoceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MGRX 0
— JNJ 9
▲ PIOTROSKI F-SCORE QUALITY LEADER: JNJ
LAST: $0.25 (-1.47%) • MKT CAP: $5.7M
piotroski-score
3/9
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MGRX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MGRX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.90% | 67.90% | -13.00 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -26.00% | 6.00% | -32.00 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.59 | -5.39 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 3/9 | 8/9 | -5.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.1 | 62.1 | -30.04 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.7M | $662.49B | -$662.49B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MGRX REV | JNJ REV | MGRX GROSS % | JNJ GROSS % | MGRX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $456.0K | $94.19B | 54.9% | 67.9% | -$5.9M | $19.70B |
| FY 2024 | $615.9K | $88.82B | 61.7% | 69.1% | -$4.9M | $19.84B |
| FY 2023 | $731.5K | $85.16B | — | — | -$7.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MGRX // BETA —
JNJ // BETA 1.08